

Cell therapy with **tolerogenic antigen-presenting cells (tolAPC)** shows promise for treating **autoimmune diseases** and **preventing transplant rejection**.

Phase 1 trials completed:

- Type 1 diabetes
- Rheumatoid arthritis
- Crohn's disease



Highly encouraging results from a safety standpoint

We developed **MITAP** (Minimum Information about Tolerogenic Antigen-Presenting cells).



MITAP is a **reporting framework** with **checklists** that allow the scientific community to better **use** and **interpret tolAPC data**.




Facilitate experimental reproducibility



Enable data sharing + highlight differences between tolAPC products



Streamline creation of standardised tolAPC for clinical applications



MITAP is a first but important step towards producing **standardised** and **reproducible tolAPC**.